Enjoy complimentary customisation on priority with our Enterprise License!
The peptide therapeutics market size is forecast to increase by USD 17.85 billion at a CAGR of 10.03% between 2023 and 2028. The market is experiencing significant growth due to the increasing prevalence of diseases such as cancer, infectious diseases, and conditions related to smoking and alcohol abuse. Novel drugs based on peptides are being developed to address these health concerns. However, the market faces challenges including complexities in manufacturing, storage conditions, distribution policies, and high costs. To overcome these hurdles, advancements in technologies such as solid-phase reactors, purification techniques, and chemical functionalization are being employed. Long peptides are gaining popularity due to their potential therapeutic benefits. Resins and synthesis methods are being optimized to improve yield and reduce production costs. In oncology, peptide therapeutics are being used for disease management and targeted therapy. In infectious diseases, peptides are being explored for their antimicrobial properties. Overall, the market for peptide therapeutics is poised for growth, driven by the need for effective disease management and the development of innovative drugs.
Peptide therapeutics have gained significant attention in the pharmaceutical industry due to their potential to address various chronic diseases. Oral peptide delivery systems have been a game-changer in this field, enabling the administration of peptide-based therapeutics with improved bioavailability and patient compliance. Peptide-based therapeutic vaccines hold promise in oncology, particularly in cancer treatment, by stimulating the immune system to target specific tumors. Peptides also offer benefits in managing metabolic disorders such as diabetes and obesity, hormonal therapy, and osteoarthritis and osteoporosis. Peptide-based drugs show clinical benefits in treating chronic diseases like smoking, alcohol abuse, and high cholesterol.
Furthermore, novel peptide leads are being explored for their potential in developing new drugs, with peptide-based biologics and small molecule-based interventions offering target specificity and low toxicity. Clinical investigation continues to uncover the full potential of peptide therapeutics in disease management. Peptide-based drugs offer a promising alternative to traditional small molecule-based interventions and pharmacological interventions, with the potential to revolutionize the treatment landscape for various diseases.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The parenteral segment is estimated to witness significant growth during the forecast period. Peptide therapeutics have gained significant attention in the healthcare industry due to their potential to treat various chronic diseases, including cancer, metabolic disorders, hormonal therapy for diabetes and obesity, osteoarthritis, and osteoporosis. The oral delivery of peptide-based therapeutics remains a challenge due to their instability and degradation in the gastrointestinal tract. Consequently, the parenteral route, which involves administering drugs through injectable routes, has emerged as the most popular route of administration for peptide therapeutics.
Further, the market for peptide therapeutics is expected to grow significantly due to the increasing prevalence of chronic diseases and the development of novel drugs for their treatment. In the field of oncology, peptide therapeutics have shown potential in treating infectious diseases. The development of peptide therapeutics for infectious diseases is a growing area of research, with a focus on overcoming insolubility issues and improving stability. The use of peptide therapeutics in disease management is expected to expand, offering new treatment options for patients.
Get a glance at the market share of various segments Request Free Sample
The parenteral segment was valued at USD 9.50 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 45% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market is witnessing significant growth, with North America leading the global market due to the high sales volume of peptide therapeutics and the increasing number of FDA approvals for biosimilars in the region. The recent advancements in peptide synthesis and drug delivery systems are driving market expansion. The pipeline for innovative peptide-based therapeutics in North America is strong, with multiple Phase III molecules demonstrating high efficacy and anticipated launches during the forecast period. In addition, the presence of advanced healthcare infrastructure and patient assistance programs to alleviate the financial burden on patients further boosts market growth. The Cancer segment and Cardiovascular disorders are the major application areas for peptide therapeutics in North America.
Furthermore, the Peptide-drug conjugates segment and the Hybrid technology segment are expected to witness significant growth due to their potential to enhance therapeutic efficacy. The market is segmented into In-house manufacturing, Outsourcing manufacturing, Parenteral route, Pulmonary route segment, and GLP-1 receptor agonists. The In-house manufacturing segment dominates the market due to the increasing trend of vertical integration among pharmaceutical companies. The Outsourcing manufacturing segment is expected to grow at a significant rate due to the cost advantages offered by contract manufacturing organizations. The Pulmonary route segment is gaining popularity due to the development of innovative technologies for the delivery of peptide therapeutics through this route. The market is anticipated to grow at a steady pace during the forecast period, driven by the increasing demand for peptide-based therapeutics in the treatment of various diseases, including Cancer, Cardiovascular disorders, and Respiratory diseases.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of infectious diseases is the key driver of the market. Peptide therapeutics have emerged as a promising solution in combating various infectious diseases caused by organisms such as bacteria, viruses, fungi, and parasites. The increasing prevalence of drug-resistant pathogens has necessitated the development of novel therapeutic approaches. Peptide-based drugs offer several advantages, including their ability to mimic the natural 3D conformational structures of proteins and target specific receptors. Synthesizing peptides involves complex processes, including purification, which can generate significant waste. Creative Peptides, a leading peptide manufacturer, employs advanced techniques to minimize waste and ensure high-quality products. The purification process is crucial in removing impurities and ensuring the therapeutic efficacy of peptides.
Furthermore, manufacturing peptide therapeutics can be expensive due to the need for specialized equipment. Recombinant peptides, which are produced using genetically engineered organisms, have gained popularity due to their cost-effectiveness and scalability. However, insolubility issues can arise during the manufacturing process, necessitating the use of solubilizing agents. Clinical trials are essential in evaluating the safety and efficacy of peptide therapeutics. In the metabolic segment, peptide therapeutics have shown significant potential in the treatment of various diseases, including diabetes, obesity, and cardiovascular diseases. The market for peptide therapeutics is expected to grow significantly due to the increasing prevalence of chronic diseases and the development of novel therapeutic approaches. However, the high manufacturing costs and the complexities involved in synthesizing and purifying peptides remain challenges that need to be addressed.
Collaboration for R&D is the upcoming trend in the market. The market has experienced significant growth due to the increasing number of approvals for peptide-based drugs in recent years. This trend can be attributed to the strategic collaborations among market players aimed at advancing research and development in novel therapies. Companies are forming alliances to address technological and research challenges, such as the transfer of technology, collaborative studies in specific regions, and regional regulatory support.
Furthermore, synthesizing peptides with precise 3D conformational structures remains a complex process, necessitating expensive manufacturing equipment. The purification process also generates considerable waste. Creating insoluble peptides is a common challenge, and companies are focusing on recombinant peptides to address this issue. Clinical trials for peptide therapeutics, such as Adlyxin, Ozempic, and Xultophy, are ongoing to evaluate their efficacy and safety in various indications.
Complexities in manufacturing, storage conditions, distribution policies, and high costs is a key challenge affecting market growth. Peptide therapeutics represent a significant and growing segment in the pharmaceutical industry due to their ability to mimic the functions of natural proteins and peptides in the body. However, the manufacturing process of peptides is more complex than that of small-molecule drugs, as they are derived from living organisms. The process includes steps such as fermentation, clarification, separation, and purification. The separation and purification processes are particularly challenging due to the subtle differences in 3D conformational structures among various peptides. These differences can lead to insolubility issues and waste generation during the manufacturing process. Creative Peptides, a leading peptide synthesis company, employs advanced techniques such as solid-phase peptide synthesis and recombinant peptide production to overcome these challenges.
However, the manufacturing process remains expensive due to the requirement for specialized equipment and the lengthy purification process. Clinical trials for peptide therapeutics, such as Adlyxin, Ozempic, and Xultophy, have shown promising results, but the high cost of production and potential for contamination during the manufacturing process poses significant challenges. To ensure product quality and consistency, analytical methods like high-performance liquid chromatography (HPLC) and spectroscopy are employed throughout the process. Proper temperature, pressure, and pH control are also essential to maintain the stability of the peptides. Despite these challenges, the metabolic segment of the market is expected to grow significantly due to the increasing demand for treatments for metabolic disorders.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amgen Inc. - The company offers Therapeutic proteins which are extensively used for the treatment of cancer, HIV, and other diseases.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Peptide therapeutics represent a significant segment in the biotech sector, offering innovative solutions for various chronic diseases, including cancer, metabolic disorders, hormonal therapy for diabetes and obesity, osteoarthritis, and osteoporosis. Oral peptide delivery and peptide-based therapeutic vaccines are emerging areas of interest, addressing challenges such as insolubility issues and high manufacturing costs. Novel drugs like Adlyxin, Ozempic, and Xultophy, which target the GLP-1 receptor, have received FDA approvals in the metabolic segment. The market encompasses the development of long peptides through synthesis using solid-phase reactors and chemical functionalization on resins. The purification process involves the use of creative peptides and expensive manufacturing equipment to ensure API stability and target specificity, with minimal toxicity profiles.
Furthermore, the market includes various segments, such as oncology, infectious diseases, cardiovascular disorders, and respiratory diseases. Peptide-drug conjugates, cell-penetrating peptides and peptide-drug conjugates are innovative approaches to address specific disease indications. The clinical benefits of peptide-based drugs lie in their target specificity and low toxicity, making them attractive alternatives to small molecule-based interventions and pharmacological interventions. Clinical investigation and clinical studies are crucial for pipeline molecules, with dosing frequency, CROs, and CMOs playing significant roles in the development process. The market also includes big pharma players and orphan drug designation for niche indications. The future of peptide therapeutics lies in hybrid technology segments and the outsourcing manufacturing segment to cater to the growing demand for these therapeutics.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
148 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
|
Market growth 2024-2028 |
USD 17.85 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
8.88 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 45% |
|
Key countries |
US, Germany, China, UK, and Canada |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Almac Group Ltd., AmbioPharm Inc., Amgen Inc., AstraZeneca Plc, Bachem AG, Bristol Myers Squibb Co., Corden Pharma International GmbH, Eli Lilly and Co., Ever Pharma, F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Ipsen Pharma, Lonza Group Ltd., Novartis AG, Novo Nordisk AS, PeptiDream Inc., Pfizer Inc., PolyPeptide Group, Sanofi SA, Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Worg pharma |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Route of Administration
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
